Mexico is carving out a place on the global health stage with an increasing number of international companies choosing to set up Latin American headquarters in the country and with its CROs fighting for a bigger slice of the clinical research pie. The year 2016 was one of change in the Mexican public health sector, highlighted by new leadership and new policies promoting cost-effectiveness and efficiency. Mexico has continued to attract an increasing number of clinical trials and new companies, bringing fresh ideas and scientific innovation. An oncoming wave of patent expirations has further prompted medicinal innovation, with Big Pharma companies racing to discover the next big treatment while others prepare to release life-saving generics and biosimilars.
